Ohmcraft Precision Resistors Play Critical Role in Accuracy of Mass Spectrometry Measurements

ROCHESTER, NY, UNITED STATES, July 20, 2018 /EINPresswire.com/ — For nearly two decades, leaders in mass spectrometry have relied on Ohmcraft’s precision resistors to manufacture extremely precise, high-voltage power supplies used in their equipment. Mass spectrometry is an analytical technique that provides advanced chemical analyses of organic samples for a variety of applications, from pharmaceuticals to breweries.

“Regardless of the application, the precision of these power sources ensures the accuracy of the sample measurement. If an error were to occur at any point in the process, the results would be compromised. That makes Ohmcraft’s leaded resistors an indispensable piece of the puzzle,” said Eric Van Wormer, Vice President of the Ohmcraft division of Micropen Technologies. “Mass spectrometry manufacturers choose Ohmcraft resistors for their unique power supply requirements.”

Larger than the handheld X-ray fluorescence (XRF) counterpart, mass spectrometry equipment has become more affordable over the years, gaining widespread popularity in industries with a need for extremely accurate results. Originally developed for pharmaceutical and biotech companies, the machines are now used by paint manufacturers, wineries, and breweries, as well as forensic investigators.

Ohmcraft’s thick-film, leaded resistors are engineered to meet this application’s specific needs. Its technology utilizes the proprietary Micropen electronic printing system to “print” precise, narrow, serpentine lines with resistive ink on a ceramic substrate, producing higher performance resistors over a wider range of values on a smaller surface area than is possible with conventional film resistor technology.

About Ohmcraft
Ohmcraft’s thick-film, leaded resistors are engineered to meet application specific needs. Our proprietary Micropen printing technology is the foundation for Ohmcraft’s family of resistor products. Ohmcraft precision leaded resistors are manufactured with our patented Micropen technology to create a unique serpentine design that withstands voltages up to 100kV and provides an unmatched level of performance and stability. For more information, visit Ohmcraft.com.

Heather Kowalczyk
McDougall Communications
585-434-2148
email us here


Source: EIN Presswire

FDA releases Biosimilar Action Plan – Hear more at this year’s Biosimilars USA conference

Biosimilars USA 2018

Following FDA’s release of Biosimilar Action Plan, this year’s Biosimilars USA conference promises to explore the developments in biosimilar drug development

LONDON, WATERLOO, UNITED KINGDOM, July 19, 2018 /EINPresswire.com/ — As the world of biosimilars gains more traction and promise, and the FDA announces the release of a long-awaited Biosimilar Action Plan, SMi’s 5th Annual Biosimilars USA Conference, taking place in New Jersey, USA on the 14th and 15th November 2018, aims to give crucial updates to biosimilar experts and scientific pioneers across the world in this rapidly evolving industry.

During a speech given this week in Washington, DC, FDA Commissioner Scott Gottlieb, MD, announced the release of the long-awaited Biosimilar Action Plan. The plan is designed to promote biosimilar competition in the US marketplace by addressing the following 4 key areas:

• Improving the efficiency of the biosimilar and interchangeable product development and approval process
• Maximizing scientific and regulatory clarity for the biosimilar product development community
• Developing effective communications to improve understanding of biosimilars among patients, providers, and payers
• Supporting market competition by reducing gaming of FDA requirements or other attempts to unfairly delay market competition to follow-on products

“While less than 2% of Americans use biologics, they represent 40% of total spending on prescription drugs,” said Gottlieb. “So, enabling a path to competition for biologics from biosimilars is a key to reducing costs and facilitating more innovation.” [centerforbiosimilars.com]

Also in recent news were statements made by the chair of this year’s two-day conference; Richard DiCicco, the chairman of Harvest Moon Pharmaceuticals USA. Richard expressed his views on Amgen, which he claims has the ability to take advantage of the unique dynamics and inefficiency of the US market as Mylan recently announced WAC for biosimilar Neulasta at $4,175/syringe and Amgen set Neulasta's WAC at $6,231, and its ASP dropped to $4,453 in the July CMS report.

According to Richard, if Mylan's biosimilar ends up as a market failure, this suggests that the US market does not allow adoption of lower-priced drugs unless the US healthcare system adapts. With both timing and pricing pressure (and Amgen is ready to protect Neulasta with bundled contracts), Richard expects Mylan to quickly move toward conversations with payers, and commercial uptake of this biosimilar will depend upon negotiation success. Richard also states that whether this biosimilar is a success or a failure has larger implications for the total success or failure of the US biosimilar market.

This year’s Biosimilars USA conference will provide delegates with the opportunity to hear from a selection of in-depth keynote addresses and case studies presented by top manufacturing and leading distributors of market-approved biosimilars, as they offer a unique insight into the areas of manufacturing, commercialization, device design, uptake, switching, interchangeability, and regulations.

The latest conference brochure, as well as other exclusive content including the full speaker line-up and an interview with expert speaker Hillel Cohen, Executive Director, Scientific Affairs, Sandoz Inc, are now available to download on the event website, where you can also register your place: www.biosimilars-usa.com/einpr

Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

Biosimilars USA
14th – 15th November 2018
Renaissance Woodbridge Hotel, 515 US Highway 1 South, Iselin, New Jersey, USA
www.biosimilars-usa.com/einpr

Follow us @SMiPharm
#SMiBioSimUSA

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
02078276000
email us here


Source: EIN Presswire

Just Imagine If We Had Oprah and Her Experts Pushing for Emotional Health(EH) Instead of EI!

Brain and mind are two separate entities and so mind and brain education are different.

The quality of the self-image determines the quality of life for individuals, groups and countries.

Wisdom power is emotional health power.

Emotionally Healthy Brain Generates Emotional Intelligence.

Create your pure self by healing your brain through brain education.

Stop letting your emotional baggage rule your life.

EI is the smoke where emotional health (EH) is the fire, yet our experts keep trying to create the smoke instead of lighting the fire.

Oprah & her experts must wake up to the true nature of EI. EI is a fragrance of an emotionally healthy brain and like all fragrances it cannot be created on its own. The brain has to be healed into EH”

— Sajid Khan

WASHINGTON, DC, USA, July 19, 2018 /EINPresswire.com/ — It is amazing that our experts have focused on emotional intelligence, even though it is a secondary entity. It is a fragrance of the brain, which means emotional intelligence cannot be created on its own, just like to improve the fragrance of a flower, the plant has to be improved.

We have tens of thousands of books explaining and defining emotional intelligence as an independent stand-alone entity. So our experts continue to try to teach emotional intelligence directly as if it is a subject like math or science! Emotional intelligence is a sport where it is the brain that has to be trained to generate healthy biochemicals.

Oprah and her experts continue to try to find better and better ways to teach emotional intelligence. It is like trying to find better and better ways to create smoke without lighting the fire. Just imagine how easy it will be to create smoke by lighting the fire. The fire, in this case, is emotional health (EH).

Just Imagine if we had Oprah and Her Experts Pushing for Emotional Health(EH) instead of EI!

Oprah has done immortal work in taking up emotional intelligence and helping it become center stage. However, her accomplishments will remain half-baked as long as she does not help define the true nature of emotional intelligence. Emotional intelligence springs from emotional health so her focus must shift to creating emotional health.

Look at the consequences of not figuring out the true nature of EH!

Ei is the smoke where EH is the fire. If only Oprah and our experts would focus on creating EH instead of EI, the mess in society and in education will melt away.

For decades Oprah and her experts have marketed EI and now when I am pointing out to her that she needs to correct this blunder and if she still continues to push for EI, and not push EH instead; then she leaves me no choice but to challenge her and her experts to prove me wrong.

Sajid Khan
4th R Foundation
2018141808
email us here

EI, wisdom and all emotions can now be measured. Thus making EI and wisdom into a science.


Source: EIN Presswire

GRC International Group PLC Launches brand new e-learning business arm

ELY, CAMBRIDGESHIRE, UNITED KINGDOM, July 19, 2018 /EINPresswire.com/ — GRC International Group PLC, the leading provider of cyber security and data compliance products and services, has strengthened its existing e-learning business with the announcement of a brand new company within the Group.

GRC eLearning’s strategy is to extend its capability beyond its core IT Governance one-stop-shops, enabling clients to access a broader range of e-learning, both off-the-shelf and custom-developed, than was previously possible. Learn more about the business here.

Existing IT Governance staff awareness e-learning courses will be hosted by GRC eLearning, including GDPR, Information Security and ISO 27001, PCI DSS and Phishing and Ransomware. The range of subjects will extend to cover related laws and management system standards.

Alan Calder, CEO of parent company GRCI, the worldwide provider of governance, risk management and compliance products and services, said: “This is another exciting step for the IT Governance family within the GRC International Group. With organisations more focused on staff training than ever before we look to utilise our already established customer base to bring these organisations the very best e-learning solutions they need.”

Organisations looking to invest in e-learning can take advantage of the 15% introductory discount available on all products today. Just add the products to your basket and your discount will be added automatically at checkout. You can also follow GRC eLearning on Facebook, Twitter and Linkedin.

GRC eLearning Ltd (www.grcelearning.com) is incorporated in the United Kingdom and helps organisations source, deploy and/or integrate an appropriate mix of staff awareness solutions that focus on cyber security, data protection, legal compliance and management standards such as ISO/IEC 27001 and ISO 22301.

– Ends –

FOR FURTHER INFORMATION

Mihaela Jucan
Marketing Ex
+44 (0) 845 070 1750
mjucan@itgovernance.co.uk

Liam Papworth
IT Governance
+ 44 3338007000
email us here


Source: EIN Presswire

Why Use Custom Lab Furniture in a Clinical or Medical Laboratory?

Modular Sample Processing

Modular Sample Processing

Do you need conventional lab benches or custom lab furniture? Read these 5 situations when it is preferred to order custom lab furniture.

There are three watchwords that measure operational success: efficiency, accuracy, and safety.”

— Formaspace

AUSTIN, TEXAS, UNITED STATES, July 18, 2018 /EINPresswire.com/ — We take a look at the reasons why leading Formaspace laboratory customers, like Quest Diagnostics, Antech Diagnostics, and Ariosa Diagnostics, as well as hospital systems like Baylor Scott & White, choose custom Formaspace integrated laboratory furniture to create highly efficient, accurate and safe lab working environments.

integrated modular lab furniture

In contrast to small scientific laboratories (designed for individual teams of researchers), the needs of large, centralized laboratories are decidedly different.

While successful experimentation and discovery might be the primary objective in a research laboratory, in a large centralized laboratory environment, there are three watchwords that measure operational success: efficiency, accuracy, and safety.

Efficiency means the ability to process a large throughput of test samples.

Accuracy means the test results are correct, consistently repeatable, and as error-free as humanly possible.

Safety means that personnel are not exposed in any way to unhealthy conditions or suffer workplace accidents.

What’s the best way to obtain these high-performance objectives at your facility?

From our experience in working hands-on with hundreds of laboratory clients, ranging from Quest Diagnostics, Antech Diagnostics, and Ariosa Diagnostics, as well as hospital systems like Baylor Scott & White, we think the following five guidelines are the basis of achieving success:

1. Create order out of chaos at your clinical hospital or medical laboratory with Integrated Lab Services from Formaspace.
High-throughput clinical laboratories, by their nature, tend to be very capital intensive.

Laboratory testing companies, healthcare organizations, and government agencies are investing millions of dollars in equipment to automate the processing of test samples.

Compared test equipment found in small-scale labs, individual pieces of laboratory equipment in centralized clinical or medical laboratories tends to see much more use throughout the day; in some cases, laboratory workers will use the equipment in multiple shifts around the clock to keep up with demand.

As a result, the laboratory layout and furniture design need to have provisions to facilitate both regular and unexpected maintenance outages. To maintain productivity, maintenance technicians and engineers need to be able to access equipment, either by quickly removing it and replacing it with a spare unit or by performing maintenance service in situ – without disrupting or shutting down other parts of the laboratory.

Here is where things can get complicated.

Read more … https://formaspace.com/articles/laboratory-furniture/use-custom-lab-furniture-in-clinical-medical-laboratory/?utm_source=einpresswire&utm_medium=content&utm_campaign=article-022117

Brooke Turner
Formaspace
8002511505
email us here


Source: EIN Presswire

Impact of "IP Literacy" is the Focus of 2018 IP Awareness Summit at Columbia University

The Center for IP Understanding will hold IPAS 2018, a global event devoted to increasing IP understanding for all

IPAS 2018 will explore the role of patents and other IP rights in a in an information-driven world and look at ways to communicate IP’s vital link to innovation, commerce and society”

— Brian Hinman, Chief Innovation Officer, Aon IP Solutions

NEW YORK, NEW YORK, USA, July 17, 2018 /EINPresswire.com/ — The Center for Intellectual Property Understanding (CIPU) announced today that it is holding this year’s Intellectual Property Awareness Summit in New York on November 29 at Columbia University in the School of Journalism.

Confusion about the purpose and use of inventions, authored works and designs, and their rights, has led to widespread IP theft on the part of both individuals and businesses. Uncertainty inhibits innovation and competition, increases frustration and discourages investment. IPAS 2018 will examine ways to improve audiences’ basic IP awareness and appreciation.

The second annual Intellectual Property Awareness Summit – IP Literacy in a Digital World – will examine the impact of information and speed on how intellectual property is seen and often taken for granted, and ways to address it through education and the media.

IPAS 2017 (Enhancing Value Through Understanding), held at Illinois Institute of Technology/ Chicago-Kent College of Law, drew participants and panelists from the U.S., Europe and Asia, and provided opportunities to network and share ideas. Discussions included best ways to address the widespread confusion over IP rights, and the growing acceptance of IP theft.

Participants included Hon. Randall Rader, former Chief Judge of the Court of Appeals for the Federal Circuit (ret.); Q. Todd Dickinson, ex-United Stated Under Secretary of Commerce, USPTO Director, Scott Frank, CEO of the IP Businesses at AT&T, Stephen Haber Director of Stamford’s IP² think tank and David Teece, UC Berkeley economist and IP advocate.

IPAS 2018 attendees will include IP holders, executives, educators, creators, service providers and IP organizations. Space is limited. To request an invitation, write explore@understandingip.org. Participants can expect interaction, networking and exploring the role of such groups as government, the media, and educators in making IP rights more intelligible, and the impact of failing to.

“Knowing what IP rights achieve is not just for lawyers,” said Bruce Berman, Chairman and founder of CIPU, an independent non-profit hosting IPAS 2018. “Patents and other IP are too important to ignore and not that difficult for most people to understand. IP is more easily accessible and easily infringed than ever, and many believe it is simply there for the taking.”

IP rights are central to more than 200 years of U.S. history. However, they have grown weaker and less certain over the past decade. Other nations are keenly aware. China, for example, has dramatically improved the reliability of its patent system and increased its investment in technology, which is threatening to dethrone the U.S. as the “go-to” nation for innovation and new ideas. A range of people and institutions that rely on IP need to know what is at stake and how to fix it.

“IPAS 2018 will explore the role of patents and other IP rights in a in an information-driven world,” said Brian Hinman, Chief Innovation Officer at Aon IP Solutions and a CIPU board member. “Everyone should be able to recognize and respect IP rights. This event will examine how to improve basic IP awareness and appreciation. IPAS speakers and panelists will look at ways to communicate IP’s vital link to innovation, commerce and society.”

For a draft of the IPAS 2018 program and event website, visit www.ipawarenesssummit.com. Watch for updates. To register, go here.

About the Center for IP Understanding

The Center for Intellectual Property Understanding is an independent, non-profit organization dedicated to increasing awareness of IP rights and their impact on people’s lives. CIPU provides information, conducts research and facilitates activities that seek to make IP more intelligible, enhance value and deter theft. The Center also tracks attitudes toward IP rights, including patents, copyrights, and trademarks, and through outreach, provides an education framework for understanding how IP promotes competition and creates jobs. To learn more, please visit www.understandingip.org.

Bruce Berman
Center for IP Understanding
212.508.9664
email us here


Source: EIN Presswire

Co-Diagnostics Announces Submission of CE Mark Registration for Tuberculosis Screening Test

Company’s Logix Smart™ MTB Test to be available for purchase with CE mark in August 2018

LONDON, UNITED KINGDOM, July 17, 2018 /EINPresswire.com/ — Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test technical file has been submitted for registration with the European Community, and that the CE marked in vitro diagnostic (“IVD”) is expected to be available for purchase early in August in markets that accept a CE mark as valid regulatory approval.

The technical file dossier and CE marking confirms that the test meets the Essential Requirements of the European Community’s In-Vitro Diagnostic Medical Device Directive (IVDD 98/79/EC). The registration process is expected to be complete by the end of July, at which point sales of the product may commence as an IVD with the CE marking included. The Logix Smart MTB Test detects DNA of mycobacteria tuberculosis (MTB) complex members and functions via real-time polymerase chain reaction (PCR) to detect and amplify the IS6110 and MPB64 regions of the MTB genome.

The newest iteration of their MTB screening test has been tailored to target detection of the two genes present in a broad range of tuberculosis infections, to greatly mitigate the potential of false negatives and improve the diagnosis and prognosis of patients afflicted with this disease worldwide. It is built on Co-Diagnostics’ proprietary CoPrimer™ design platform to virtually eliminate “primer-dimers,” the often-occurring phenomenon that leads to false positives in these types of diagnostics.

The key component to battling tuberculosis is an early, accurate, and affordable diagnosis. The Company believes that this will help them to better meet the global demand for detection of a disease with 99.9% of infections occurring outside of the United States, and that causes over 1.5 million deaths per year. Roughly 95% of these deaths occur in low and middle-income countries, which includes those in Eastern Europe in addition to many across Central America and the Caribbean basin. In the case of the latter, the Departments or Ministries of Health recognize clearance by the European Community as valid regulatory approval to allow sale of CE marked products throughout their jurisdictions.
Click here to read more about Co-Diagnostics.

This Press Release has been prepared by the Healthcare Trends Team of The Wall Street Club.

Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company and The Wall Street Club undertake no obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

European Office
BDA International Investor Relations
+34 932688282
email us here


Source: EIN Presswire

New grant offering signals increased role for infectious diseases specialists researching Alzheimer’s causation

Dr. Leslie Norins, an Emeritus member of the Infectious Diseases Society of America, is funding two grants to help researchers explore germs in Alzheimer's.

Despite many clues suggesting infectious agents might be triggering Alzheimer’s disease, until now there have been too few infectious disease experts involved in researching this possibility.”

— Dr. Leslie Norins

NAPLES, FL, UNITED STATES, July 17, 2018 /EINPresswire.com/ — The recently announced offering of two research grants by the Infectious Diseases Society of America Foundation signals the timely addition of a relevant medical specialty to those already seeking the causes of Alzheimer’s disease (AD), says Leslie Norins, MD, PhD, founder and CEO of Alzheimer’s Germ Quest Inc.

“This is the first time a major group of infectious disease experts feels it is worthwhile to examine the possibility of infection as a root cause of AD,” he says.

Dr. Norins predicts ripple effects far beyond the relatively small dollar amounts offered in these initial “seed research” offerings—$50,000 each—due to the stature of the group involved. The Foundation is the research and education arm of the Infectious Diseases Society of America (IDSA).

“With the recent evidence further implicating herpes virus as a possible trigger for AD, and the new concept that the amyloid plaques and tangles in the afflicted brain may represent the body’s immune reaction to infectious agents, there is no more pertinent specialty than infectious diseases to help extend these beachheads,” he says.
IDSA is the principal U.S. organization for specialists in infectious diseases, Dr. Norins says, and among other activities provides board certification. It has over 11,000 members. He is an emeritus fellow of the group.

Dr. Norins adds, “Despite many clues suggesting infectious agents might be triggering Alzheimer’s disease, until now there have been too few infectious disease experts involved in researching this possibility.” He attributes this lack of prior involvement to the paucity of research funds allocated by government and advocacy group funders for worthwhile investigations on infectious possibilities. “Most of the billions of dollars in AD grant money for years has been reserved for the more traditional studies of amyloid plaques and protein tangles. Now research on germ involvement must get a fair share,” he says.

The grants were made possible by a donation to the Foundation by Dr. Norins and his wife Rainey Norins. Grant applications can be obtained from foundation@idsociety.org.

Alzheimer’s Germ Quest, Inc. is a public benefit corporation headquartered in Naples Florida. Its mission is to accelerate and deepen scientific investigations into the possible role of infectious agents as the root cause of Alzheimer’s disease. It is the sponsor of the $1 Million Alzheimer’s Germ Quest Challenge Award for scientists. (ALZgerm.org).

Mollie Page Griffin
Alzheimer's Germ Quest
2397777243
email us here


Source: EIN Presswire

First-ever commercial diagnostic test for deadly equine virus now available

 NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population.To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population.

 To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this campaign.

The team is offering NEV tests as a reward for the backers and more details are available on the Indiegogo campaign page of the project.A veterinarian is required to take the horse’s blood, which is sent to the Equigerminal lab where it is tested and then results sent

New Equine Virus (NEV) was first identified in 2013 by Isabel Fidalgo Carvalho and Alexandre Pires. Isabel and Alexandre went on to found Portugal-based equine biotech firm Equigerminal in order to develop an accurate and commercially viable NEV diagnostic test.

We have spent the last five years developing a diagnostic test and a potential cure for NEV”, explains Pires. “We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

A diagnostic test, able to identify a deadly virus believed to be present in up to 10% of horses, is now available for the first time for horse lovers.

Our world is interconnected
'The greatest danger to our future is apathy' for animal diseases and the spread of virus with zoonotic potential!
ACT against a new deadly equine virus, similar to HIV.”

— Isabel Carvalho

COIMBRA, COIMBRA, PORTUGAL, July 16, 2018 /EINPresswire.com/ — Equigerminal is an established biotech company specialising in equine health. It already offers more than 60 lab-testing services to horse owners and vets.
Equigerminal hopes to develop further equine healthcare and welfare products and services, such as DNA testing services and pathogen screening to aid the world’s almost 70 million horses.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population. To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this fundraising campaign and their goal is to raise a sum of EUR 15,000.

New Equine Virus (NEV) was first identified in 2013 by Isabel Fidalgo Carvalho and Alexandre Pires. Isabel and Alexandre went on to found Portugal-based equine biotech firm Equigerminal in order to develop an accurate and commercially viable NEV diagnostic test that can be used by vets, vet labs and horse owners.

After many years of research and testing the diagnostic test is now launching to the equine community.

NEV – the equine equivalent of HIV – is often misdiagnosed or hidden by other diseases that induce similar symptoms, like anemia and neurological issues in horses. It is most commonly confused with the West Nile Virus, Swamp Fever virus (EIAV) and Equine Herpesviruses (EHV)

Horses thought to have the highly-contagious Swamp Fever can be ordered to be culled by officials in an attempt to stop its spread – a tragedy for the horses, and highly distressing and costly for owners.

By testing a number of horses with anemia Equigerminal researchers first believed they had found the presence of a divergent strain of the Swamp Fever Virus (EIAV) – because the horses cross reacted with EIAV, but were negative in the official tests (the Coggins test). But subsequent research found they were actually suffering from NEV

NEV, which can lead to severe neurological diseases and also prove fatal, can now be identified through the use of the new diagnostic test developed by Equigerminal.

A veterinarian is required to take the horse’s blood, which is sent to the Equigerminal lab where it is tested and then results are returned to the owner/vet.

Once the horse has been tested the appropriate treatment can be given and the spread of the disease prevented. The treatment is currently targeted towards improving the general well-being of the horse, health monitoring, and boosting the animal’s immune system. The next stage is to find a treatment, and ideally a cure for NEV.

NEV was discovered by Portuguese scientist, veterinarian and entrepreneur Isabel Fidalgo Carvalho while completing her PhD in Equine Sciences at the Universities of Oporto and Pittsburgh.

“During my time at University and at Equigerminal, I noticed unusual anemia and severe neurological signs in horses, which in my PhD I wrongly hypothesized to be attributed to Swamp Fever”, says Carvalho.

“I realized through the samples that this virus was actually closer to equine HIV – New Equine Virus, or NEV”.

Carvalho launched Equigerminal in 2011 with fellow equine scientist, inventor and entrepreneur, Alexandre Vieira Pires.

“We have spent the last five years developing a diagnostic test and a potential cure for NEV”, explains Pires.

“We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

Equigerminal hopes to develop further equine healthcare and welfare products and services, such as DNA testing services and pathogen screening to aid the world’s almost 70 million horses.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population. To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this fundraising campaign and their goal is to raise a sum of EUR 15,000.

The Indiegogo Campaign is located on the web at:
www.indiegogo.com/projects/equigerminal-pets and supporters from around the world can back this project by making generous pledges and donations. Everyone, especially pet lovers and those who care about saving a major chunk of horse population are welcomed to participate in the fundraising. The team is offering NEV tests as a reward for the backers and more details are available on the Indiegogo campaign page of the project.

About This Project
Equigerminal is a horse biotech company based in Europe and it has recently discovered a new lentivirus that affects horses. The new virus is called New Equine Virus (NEV) and it is a serious threat to the horse population worldwide. The team of scientists is now raising funds and support to counter this threat via Indiegogo and it is welcoming everyone for generous community backing.

Isabel Carvalho
Equigerminal SA
239094666
email us here

We’ve identified a New Equine Virus, similar to HIV, developed tests and antivirals to control it.


Source: EIN Presswire

Dr. Srini Pillay, Reveals 5 Counterintuitive Ways to Benefit From Psychotherapy

Dr. Srini Pillay

New research helps explain why unfocus can help you in therapy.

LOS ANGELES, CA, UNITED STATES, July 13, 2018 /EINPresswire.com/ — Dr. Srini Pillay, best-selling author of TINKER DABBLE DOODLE TRY, aptly reveals five counterintuitive ways of benefitting from psychotherapy.

“Most people request psychotherapy for a reason. Either they are overwhelmed by their own emotions or thoughts, or they have mental roadblocks that they have to navigate,” Pillay shares. “Often, people come in expecting that they will focus on their goals. But much of the value of psychotherapy actually lies in unfocusing.”

Lesson #1: “Goals” are far less obvious than they seem. When we say we have a goal, we may simply be reporting what our brains have already decided. Deeper thought may reveal that this is not what we truly want. The real goal may be obscure, so you may want to question and examine your actual goals from time to time.

Lesson #2: When you are logical, you may succumb to habit pathways in the brain. This will not help you get unstuck. One way to overcome this is to allow your mind to wander. This kind of unfocusing will turn on more “self” representations in the brain. You feel more self-connected. As a result, you will be more likely to find creative solutions to your problems.

Lesson #3: Your brain is a little like a telephone. Sometimes you may be in sync with your therapist; at other times, not. Either way, it’s helpful to look at those feelings in the interaction and not just what comes from you.

Lesson #4: Being practical is not always the best thing. Also, becoming intolerant of ambiguity and uncertainty could rob you of the power of your paradoxes, sterilizing you and removing the motivation that authenticity can bring when you are holding contradictory feelings.

Lesson #5: When therapists are reflective out loud, detailing even minutiae, it may seem that they are off track. They wouldn’t be remembering their story if you had not contributed to it. Called reverie, this could be something to explore instead of reject or ignore.

“In all of these suggestions, unfocus is key. Unfocusing from your goals, releasing the hold of logic, looking outside yourself, and opening your mind to the therapist’s rambling are all things you might want to try out,” Pillay expertly concludes.

Aurora DeRose
Aurora DeRose
310-396-6090
email us here


Source: EIN Presswire